NASDAQ:RXST RxSight - RXST Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.07 +0.32 (+2.03%) (As of 03/22/2023 02:34 PM ET) Add Compare Share Share Today's Range$15.48▼$16.4750-Day Range$12.58▼$15.7552-Week Range$9.78▼$16.99Volume141,536 shsAverage Volume137,228 shsMarket Capitalization$542.84 millionP/E RatioN/ADividend YieldN/APrice Target$18.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media RxSight MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside16.2% Upside$18.67 Price TargetShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$6 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.29) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector608th out of 983 stocksOphthalmic Goods Industry6th out of 7 stocks 2.4 Analyst's Opinion Consensus RatingRxSight has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, RxSight has a forecasted upside of 16.2% from its current price of $16.07.Amount of Analyst CoverageRxSight has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.01% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 3.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXST. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.75% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.87% of the stock of RxSight is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($2.29) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RxSight (NASDAQ:RXST) StockRxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesMarch 13, 2023 | finance.yahoo.comHow Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%March 9, 2023 | msn.comLooking Into RxSight's Return On Capital EmployedMarch 22, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. March 8, 2023 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.com5 Analysts Have This to Say About RxSightMarch 7, 2023 | finance.yahoo.comRxSight, Inc.'s (NASDAQ:RXST) biggest owners are individual investors who got richer after stock soared 14% last weekMarch 6, 2023 | finance.yahoo.comRxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 3, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on RxSight (RXST)March 22, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. March 3, 2023 | msn.comEarnings Preview: RxSightFebruary 21, 2023 | finance.yahoo.comRxSight, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 6, 2023February 8, 2023 | msn.comWhy RxSight Shares Are PlummetingFebruary 8, 2023 | finance.yahoo.comRxSight, Inc. Announces Pricing of Public Offering of Common StockFebruary 7, 2023 | msn.comRxSight launches $40M stock offeringFebruary 7, 2023 | finance.yahoo.comRxSight, Inc. Announces Proposed Public Offering of Common StockJanuary 9, 2023 | finance.yahoo.comInvesting in RxSight (NASDAQ:RXST) a year ago would have delivered you a 12% gainJanuary 8, 2023 | finance.yahoo.comRxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational ResultsDecember 31, 2022 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call TranscriptDecember 28, 2022 | finance.yahoo.comRxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comHas IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?December 6, 2022 | finance.yahoo.comIs RxSight (RXST) Stock Outpacing Its Medical Peers This Year?December 3, 2022 | finance.yahoo.comDoes RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect?December 1, 2022 | msn.comRxSight Earnings Perspective: Return On Capital EmployedNovember 16, 2022 | finance.yahoo.comWall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should KnowNovember 9, 2022 | finance.yahoo.comRxSight Third Quarter 2022 Earnings: Beats ExpectationsNovember 8, 2022 | seekingalpha.comRxSight, Inc. (RXST) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comRxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Company Calendar Today3/22/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.67 High Stock Price Forecast$22.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+18.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,760,000.00 Net Margins-136.22% Pretax Margin-136.20% Return on Equity-63.73% Return on Assets-41.10% Debt Debt-to-Equity Ratio0.45 Current Ratio7.81 Quick Ratio6.95 Sales & Book Value Annual Sales$49.01 million Price / Sales10.86 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book4.86Miscellaneous Outstanding Shares33,780,000Free Float25,079,000Market Cap$532.04 million OptionableNot Optionable Beta0.37 Key ExecutivesDr. Ronald M. Kurtz M.D. (Age 59)Pres, CEO & Director Comp: $851.06kMs. Shelley B. Thunen (Age 68)CFO & Assistant Sec. Comp: $536.65kDr. Ilya Goldshleger Ph.D. (Age 47)Chief Operating Officer Comp: $571.6kMr. Eric J. Weinberg (Age 61)Chief Commercial Officer Comp: $575.62kRebecca WillistonVP of Accounting & Fin.Mr. Matt Haller Ph.D.Chief Technology OfficerSteve EverlyVP of US SalesMr. Roy FreemanVP of MarketingCaroline VaughnVP of HRScott GainesSr. VP of Commercial Operations & Bus. ProcessMore ExecutivesKey CompetitorsWarby ParkerNYSE:WRBYNational VisionNASDAQ:EYENovavaxNASDAQ:NVAXCoherus BioSciencesNASDAQ:CHRSMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 90,723 shares on 2/15/2023Ownership: 1.425%Schonfeld Strategic Advisors LLCBought 47,800 shares on 2/15/2023Ownership: 0.172%IHT Wealth Management LLCSold 7,500 shares on 2/15/2023Ownership: 0.125%Boothbay Fund Management LLCBought 5,505 shares on 2/15/2023Ownership: 0.110%Morgan StanleySold 3,735 shares on 2/15/2023Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions RXST Stock - Frequently Asked Questions Should I buy or sell RxSight stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RXST shares. View RXST analyst ratings or view top-rated stocks. What is RxSight's stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price objectives for RxSight's shares. Their RXST share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $18.67 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts. How have RXST shares performed in 2023? RxSight's stock was trading at $12.67 at the beginning of 2023. Since then, RXST shares have increased by 24.3% and is now trading at $15.75. View the best growth stocks for 2023 here. When is RxSight's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our RXST earnings forecast. What guidance has RxSight issued on next quarter's earnings? RxSight issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.00 million-$83.00 million, compared to the consensus revenue estimate of $76.70 million. When did RxSight IPO? (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. What is RxSight's stock symbol? RxSight trades on the NASDAQ under the ticker symbol "RXST." Who are RxSight's major shareholders? RxSight's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.42%), Geode Capital Management LLC (1.10%), Point72 Asset Management L.P. (0.93%), Russell Investments Group Ltd. (0.25%), Charles Schwab Investment Management Inc. (0.19%) and Schonfeld Strategic Advisors LLC (0.17%). Insiders that own company stock include Bakker Juliet Tammenoms and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RxSight's stock price today? One share of RXST stock can currently be purchased for approximately $15.75. How much money does RxSight make? RxSight (NASDAQ:RXST) has a market capitalization of $532.04 million and generates $49.01 million in revenue each year. The company earns $-66,760,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. How many employees does RxSight have? The company employs 2,021 workers across the globe. How can I contact RxSight? The official website for the company is www.rxsight.com. The company can be reached via phone at 949-521-7830 or via email at ir@rxsight.com. This page (NASDAQ:RXST) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.